This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
phttp://www.wikidata.org/prop/
wikibasehttp://wikiba.se/ontology#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://dx.doi.org/10.1111/
n8http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q92017087
rdf:type
wikibase:Item
schema:description
wetenschappelijk artikel im April 2020 veröffentlichter wissenschaftlicher Artikel scientific article published on 17 April 2020 artículu científicu espublizáu n'abril de 2020 наукова стаття, опублікована 17 квітня 2020
p:P577
wds:Q92017087-D1D9983E-5CC4-4EEE-B665-89CC26EEA13E
wdt:P577
2020-04-17T00:00:00Z
p:P2093
wds:Q92017087-B1EC258E-7D2A-4EC8-A039-2979763BE5A3
wdt:P2093
Federico Bardazzi
rdfs:label
Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases? Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?
skos:prefLabel
Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases? Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?
schema:name
Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases? Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?
p:P50
wds:Q92017087-5E08396F-3F0E-4D4A-B54D-ABB76DDC1965 wds:Q92017087-C8664B6B-90EE-4180-8C88-F2D498B09D0A
wdt:P50
wd:Q89754381 wd:Q89971195
p:P1476
wds:Q92017087-9036B159-0614-40CC-A6F0-EB16F1FD90EC
wdt:P1476
Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?
p:P31
wds:Q92017087-9E412FF1-A279-4F6A-AE04-D455090376CF
wdt:P31
wd:Q13442814
p:P921
wds:Q92017087-6A090163-3393-4AB6-ACCC-F476016A5AAC wds:Q92017087-8E504A92-BAA1-43EF-B708-9752CA5EF10B
wdt:P921
wd:Q82069695 wd:Q84263196
p:P698
wds:Q92017087-8E7EB64A-E5BB-41DA-809E-8CB2270315D2
wdtn:P698
n8:32302437
wdt:P698
32302437
p:P1433
wds:Q92017087-3B5AC272-A85D-4995-9DE1-3F923ECC352E
wdt:P1433
wd:Q15760872
p:P356
wds:Q92017087-BA9D468D-ED18-4A8B-8570-395163BD9E33
wdtn:P356
n12:JDV.16491
wdt:P356
10.1111/JDV.16491
p:P6179
wds:Q92017087-1270485F-4D68-43C6-8809-08AA452BAAC6
wdt:P6179
1126751022
p:P8150
wds:Q92017087-A4351EE0-0301-4289-AE18-C004A0C11D35
wdt:P8150
covidwho-72081